Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01496599 · ClinicalTrials.gov registry record

Imaging Biomarkers in Parkinson s Disease

A clinical trial, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).

Completed
Registry status
62
Enrollment target

NCT01496599 is a clinical trial that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 62 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01496599 has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).

COMPLETED
Registry status
62 participants
Enrollment target

Study Summary

Background: \- Parkinson s disease (PD) causes slow movement, stiffness, and tremor. It results from the loss of a brain chemical called dopamine. PD gets worse over time, but researchers do not fully understand why the brain cells that produce dopamine stop working or die in people with PD. This study will use different ways of imaging the brain and brain chemicals to look at PD. It will compare brain imaging in people who definitely have PD to people who might have PD and to people without signs of PD. It will provide more information how the brain in people with PD changes over time. Objectives: \- To understand the changes that occur in the brains of people with Parkinson s disease. Eligibility: * Individuals at least 18 years of age who have definite or possible Parkinson s disease. * Healthy volunteers at least 18 years of age. Design: * Participants will have a screening visit with a physical exam and medical history. * Participants will visit the National Institutes of Health Clinical Center every 18 month or 3 years for up to 9 years. There will be up to 6 total visits. Most visits will last 5 to 6 hours a day for 1 to 3 days. Some or all of the following tests will be performed at each visit: * Magnetic resonance imaging to take pictures of the brain. Some of these tests will be done at rest. Others will require participants to perform an activity during the scan. * Medication withdrawal for 12 hours overnight for people taking PD medications. This may be done before some scans. Participants who feel unwell when they stop taking medications will be allowed to start taking them again. * Participants will continue with the follow up visits until the end of the study.

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2012-01-24

What the Registry Record Tells You About NCT01496599

The ClinicalTrials.gov registry entry for NCT01496599 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT01496599 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01496599 about?

NCT01496599 is a clinical study titled "Imaging Biomarkers in Parkinson s Disease". Background: \- Parkinson s disease (PD) causes slow movement, stiffness, and tremor. It results from the loss of a brain chemical called dopamine. PD gets worse over time, but researchers do not fully understand why the brain cells that produce dopamine stop working or die in people with PD. This s...

What is the current status of trial NCT01496599?

This trial is currently completed. The enrollment target is 62 participants. The study started on 2012-01-24.

Who is sponsoring clinical trial NCT01496599?

This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.